Ardelyx (ARDX) Resubmits New Drug Application to FDA.
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
Psycheceutical Bioscience Inc.’s (BWVI) Novel Topical Ketamine Delivery.
Rick Doblin, Recently Visited one of Psycheceutical's Labs.
Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted...
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.
LIVE QUOTE
Longer Term Chart
Ardelyx Enters the Danger Zone* With Tenapanor.
Maxim Group Targets 175% Gain in Society Pass (SOPA) to $2.75.
If we average out the two most recent price targets this month, we come out with a potential gain of 337% and...
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment...
Topline Results anticipated by the end of Q2 2023
CRANFORD, N.J. , April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or...
Smart for Life (SMFL) Reports Revenue Increases 96.9% to $17.8 Million for 2022
Smart for Life Reports 2022 Financial Results and Provides Business Update
(Bolding by IA Editor)
Report: Think Equity Updates Society Pass (SOPA). $6.00 Price Target.
Think Equity: Society Pass (Nasdaq: SOPA) – Path to Profitability
NEW YORK, NY, March 14, 2023 (GLOBE NEWSWIRE) --...
IA Initiates Analyst Coverage of Principal Solar (Press Release).
Principal Solar, Inc.Mon, March 20, 2023 at 7:30 AM EDT
Institutional Analyst, Inc....
And We Have a $26.4 Billion Winning Trifecta!
THREE PREVIOUS WINNERS*
Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired...
Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.
Going Short the Market. No Long Dissertation, No Rush. Market Risk Has Appeared, With Minimal Upside, So Time To Act.